340 related articles for article (PubMed ID: 12761596)
1. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
4. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Graham MC; Scher HI; Liu GB; Yeh SD; Curley T; Daghighian F; Goldsmith SJ; Larson SM
Clin Cancer Res; 1999 Jun; 5(6):1307-18. PubMed ID: 10389913
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
6. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
[TBL] [Abstract][Full Text] [Related]
8. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
Dafermou A; Colamussi P; Giganti M; Cittanti C; Bestagno M; Piffanelli A
Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074
[TBL] [Abstract][Full Text] [Related]
9. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
van Aswegen A; Roodt A; Marais J; Botha JM; Naudé H; Lötter MG; Goedhals L; Doman MJ; Otto AC
Nucl Med Commun; 1997 Jun; 18(6):582-8. PubMed ID: 9259533
[TBL] [Abstract][Full Text] [Related]
10. Systemic radionuclide therapy in pain palliation.
Liepe K; Runge R; Kotzerke J
Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
[TBL] [Abstract][Full Text] [Related]
11. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
[TBL] [Abstract][Full Text] [Related]
12. Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP?
de Klerk JM; Zonnenberg BA; van Het Schip AD; van Dijk A; Huiskes AW; van Rijk PP
Nucl Med Commun; 1999 Sep; 20(9):833-6. PubMed ID: 10533189
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
14. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
15. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
O'Sullivan JM; McCready VR; Flux G; Norman AR; Buffa FM; Chittenden S; Guy M; Pomeroy K; Cook G; Gadd J; Treleaven J; Al-Deen A; Horwich A; Huddart RA; Dearnaley DP
Br J Cancer; 2002 Jun; 86(11):1715-20. PubMed ID: 12087455
[TBL] [Abstract][Full Text] [Related]
16. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trials of
Denis-Bacelar AM; Chittenden SJ; Dearnaley DP; Divoli A; O'Sullivan JM; McCready VR; Johnson B; Du Y; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):620-629. PubMed ID: 27770145
[TBL] [Abstract][Full Text] [Related]
18. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
Breitz HB; Fisher DR; Wessels BW
J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
[TBL] [Abstract][Full Text] [Related]
19. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
Sciuto R; Festa A; Pasqualoni R; Semprebene A; Rea S; Bergomi S; Maini CL
Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096
[TBL] [Abstract][Full Text] [Related]
20. Rhenium-188-HEDP in the palliative treatment of bone metastases.
Liepe K; Hliscs R; Kropp J; Grüning T; Runge R; Koch R; Knapp FF; Franke WG
Cancer Biother Radiopharm; 2000 Jun; 15(3):261-5. PubMed ID: 10941533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]